Entering text into the input field will update the search result below

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript

Mar. 05, 2020 7:53 PM ETLisata Therapeutics, Inc. (LSTA)
SA Transcripts profile picture
SA Transcripts

Caladrius Biosciences, Inc. (CLBS) Q4 2019 Earnings Conference Call March 5, 2020 4:30 PM ET

Company Participants

John Menditto - Vice President of Investor Relations & Corporate Communications

David Mazzo - President & Chief Executive Officer

Joseph Talamo - Chief Financial Officer

Conference Call Participants

Joe Pantginis - H.C. Wainwright

Jason Kolbert - Dawson James

Steve Brozak - WBB

Pete Enderlin - MAZ Partners


Welcome to the Caladrius Bioscience Fourth Quarter and Full Year 2019 Financial Results and Business Update Conference call. Currently, all participants are in listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today Thursday, March 5, 2020.

I'll now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John Menditto

Good afternoon, and thank you all for participating in today's call. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; and Joseph Talamo, Chief Financial Officer.

Earlier today, we issued a news release announcing our 2019 fourth quarter and full year financial results. If you have not received this news release or would like to be added to the company's email distribution list, please e-mail me at jmenditto@caladrius.com.

Before we begin, I'll remind you that the comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Caladrius. I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitation its forms 10-K, 10-Q and 8-K, which identifies specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Furthermore, the content of this conference call contains time-sensitive

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.